Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for GALLIUM GA-68 PSMA-11
- PET Imaging of 68Ga-NOTA-H006 in Malignancy
- Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
- FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer
- Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms
- Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:
- Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases
- Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer
- Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
- 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
- An Investigational Scan (68Ga-FAPI-46 PET/CT) for the Imaging of Cancer-Associated Fibroblasts in Patients With Localized Pancreatic Ductal Adenocarcinoma
- Contribution of PET/CT With Gallium 68 Citrate (68Ga-PET/CT) for the Diagnosis of Prosthetic Valve Infective Endocarditis
- Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer
- Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy
- The Association of CPP-ACPF Associated With LASER in the Treatment of Tooth Sensitivity After at Home Bleaching
- 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
- PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI
- Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
- 68Ga-FAPI PET/CT in Malignant Tumors
- Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
- Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status
- The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
- Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors
- 225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC
- The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
- Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions
- An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer
- 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer
- Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
- Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
- 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
- Imaging of Solid Tumors Using 68Ga-FAP-2286
- Clinical Application of Fibroblast Activation Protein PET/MRI for Diagnosis and Staging in Malignant Tumors
- Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
- Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
- 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
- ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
- 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
- Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
- IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
- Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
- Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
- Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
- Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
- 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
- The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer
- 68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage
- PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46
- Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- The Effects of Ibuprofen and Laser on Orthodontic Pain
- 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
- 68Ga-DOTATATE PET-CTA Imaging for the Early Detection of Progressing Coronary Atherosclerosis
- An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
- 68-Ga-FAPI PET Imaging in Malignancy
- 68 Ga PSMA PET/MRI for Hepatocellular Carcinoma
- 68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
- Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
- 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
- PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
- Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
- Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
- Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
- Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer
- SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
- Comparison of PET With 68GA-PSMA-11 and 18F-Fluorocholine for Recurrence in Men With Prostate Cancer
- Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
- Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery
- Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
- Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
- Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
- 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
- 68Ga PSMA in Preprostatectomy Patients
- CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas
- Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
- Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
- Obinutuzumab in Marginal Zone Lymphoma
- Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma
- To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
- Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
- A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
- Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
- Novel Gallium 68 Citrate in Orthopedic Infections
- Novel Gallium Imaging in Hepatocellular Carcinoma
- 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
- 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
- Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
- Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
- A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma
- Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
- 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
- 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
- Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer
- LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
- 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
- Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
- Gallium-68 Citrate PET Used in Prostate Cancer
- Rituximab (RTX) Therapy in Patients With Active TAO
- Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
- A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
- GA-68 DOTA-TOC of Somatostatin Positive Malignancies
- Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
- Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
- Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients
- ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA
- Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
- Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
- A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
- Rituximab Maintenance After Autologous Transplantation
- A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients
- Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Rituximab and ABVD for Hodgkin's Patients
- Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA
- Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
- Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
- Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer
- Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
- Lupron Sex Offender Therapy
- Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
- Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
- Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma
- Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma
- Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
- Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
- Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
- Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease
- Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
- Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors
Clinical trials list
click for details